About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease ...

A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...

Aptevo Therapeutics Inc. shares surged nearly 50% early Thursday on promising leukemia trial results, before paring gains in ...

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Aptose Biosciences (APTO) announced the publication of preclinical data for Aptose’s lead hematology compound tuspetinib in Cancer Research ...

(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...